Treatment of Sleep Disorders Following Traumatic Brain Injury: A Systematic Review and Network Meta-Analysis.

J Head Trauma RehabilMar 19, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

Yancheng Wang, Jiaqing Yan, Liyao Su et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis compared pharmacological and nonpharmacological interventions for sleep disorders after traumatic brain injury. It included 22 randomized controlled trials involving 1299 patients, with sleep outcomes assessed using the ISI, PSQI, and ESS. Several nonpharmacological interventions significantly improved sleep outcomes versus control treatments: CBT, acupuncture, tDCS, and BCAA improved ISI; CBT, acupuncture, tDCS, HBOT, and PST improved PSQI; and CBT improved ESS. Pharmacotherapy did not show superior efficacy. The authors conclude that nonpharmacological approaches may help, while emphasizing the need for further high-quality research.

Key findings

  • Across 22 randomized controlled trials involving 1299 patients, several nonpharmacological interventions significantly improved sleep outcomes compared with control treatments.
  • CBT, acupuncture, tDCS, and BCAA significantly improved ISI scores; CBT, acupuncture, tDCS, HBOT, and PST significantly improved PSQI scores.
  • CBT improved ESS scores, while pharmacotherapy did not demonstrate superior efficacy.

Why it matters

Sleep disorders are a recognized concern after traumatic brain injury, and this synthesis compares a range of treatment approaches across multiple sleep measures. Its findings suggest that nonpharmacological interventions may offer benefit, while the lack of demonstrated superiority for pharmacotherapy and the call for better-quality research underscore uncertainty about comparative effectiveness.

What to keep in mind

The authors state that further high-quality research is needed to confirm the findings.

Source

Published in J Head Trauma Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.